Get the Stockscreener App
6.46
4.01%
-0.27
After Hours:
6.46
Aptevo Therapeutics Inc stock is traded at $6.46, with a volume of 43,010.
It is down -4.01% in the last 24 hours and up +7.49% over the past month.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
See More
Previous Close:
$6.73
Open:
$6.65
24h Volume:
43,010
Relative Volume:
0.25
Market Cap:
$6.45M
Revenue:
$12.99M
Net Income/Loss:
$-23.72M
P/E Ratio:
-0.0664
EPS:
-97.2514
Net Cash Flow:
$-23.28M
1W Performance:
-12.11%
1M Performance:
+7.49%
6M Performance:
-77.71%
1Y Performance:
-99.35%
1-Day Range:
$6.46
$6.77
1-Week Range:
$6.45
$7.415
52-Week Range:
$5.94
$1,299.60
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Name
Aptevo Therapeutics Inc
Sector
Industry
Phone
206-838-0500
Address
2401 4TH AVE., SEATTLE, WA
Compare APVO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
6.46 | 6.72M | 12.99M | -23.72M | -23.28M | -97.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-05-17 | Resumed | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Stock (APVO) Latest News
10 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
APVO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aptevo Therapeutics (NASDAQ:APVO) Upgraded at Wall Street Zen - Defense World
Retail Surge: Can Moodys Corporation reach resistance levels soon2025 Momentum Check & Safe Entry Point Identification - baoquankhu1.vn
APVO SEC FilingsAptevo Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Aptevo Therapeutics Inc expected to post a loss of $8.10 a shareEarnings Preview - TradingView
Aptevo Therapeutics Shareholders Approve Expanded Equity Financing Capacity - TipRanks
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Institution Moves: How volatile is FATBW stockJuly 2025 Drop Watch & Expert Curated Trade Ideas - baoquankhu1.vn
Aptevo Therapeutics (APVO) sees Point72 report 0% ownership - Stock Titan
Seattle biotech CEO to step down, replacement named - The Business Journals
Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket - Intellectia AI
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Drop in Short Interest - Defense World
Will Aptevo Therapeutics Inc. stock remain a Wall Street favorite2025 Performance Recap & Long-Term Investment Growth Plans - mfd.ru
Will Aptevo Therapeutics Inc. be affected by tariffsCPI Data & AI Based Buy and Sell Signals - mfd.ru
Can Aptevo Therapeutics Inc. navigate macro headwindsJuly 2025 News Drivers & Technical Buy Zone Confirmation - mfd.ru
What is Aptevo Therapeutics Inc.’s valuation compared to sectorM&A Rumor & Accurate Entry/Exit Alerts - mfd.ru
Why Aptevo Therapeutics Inc. stock attracts high net worth investorsProduct Launch & Real-Time Market Sentiment Alerts - mfd.ru
Is Aptevo Therapeutics Inc. stock a value trapQuarterly Portfolio Review & Scalable Portfolio Growth Ideas - mfd.ru
Aug Rallies: What is Aptevo Therapeutics Inc. s 5 year growth outlookJuly 2025 Setups & Verified Entry Point Detection - mfd.ru
Risk Report: Is Aptevo Therapeutics Inc impacted by rising ratesChart Signals & Safe Swing Trade Setups - baoquankhu1.vn
Is Aptevo Therapeutics Inc. stock a top momentum playSell Signal & Reliable Entry Point Alerts - mfd.ru
Aptevo Therapeutics Announces CEO Transition and Leadership Changes - The Globe and Mail
Aptevo Therapeutics announces leadership changes as CEO retires By Investing.com - Investing.com Canada
Aptevo Announces CEO Changes - marketscreener.com
Aptevo Therapeutics Inc. Announces Board and Executive Changes - marketscreener.com
Aptevo Therapeutics Names Jeff Lamothe President and CEO as Marvin White Becomes Executive Chair - citybiz
Is Onto Innovation Inc stock risky to hold now2025 Support & Resistance & Detailed Earnings Play Strategies - baoquankhu1.vn
Aptevo Therapeutics (APVO) Announces Changes in Leadership to Pr - GuruFocus
Aptevo Therapeutics IncMarvin White to retire as Aptevo CEO effective April 1, 2026SEC filing - marketscreener.com
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth - The Globe and Mail
Aptevo Therapeutics announces leadership changes as CEO retires - Investing.com
Aptevo (NASDAQ: APVO) elevates COO Jeff Lamothe to succeed CEO Marvin White - Stock Titan
Cancer drug developer Aptevo hands CEO role to operations chief - Stock Titan
Aptevo Therapeutics (APVO) Announces Offering of 7.075 Million S - GuruFocus
Aptevo Therapeutics prospectus relates to offer and sale of up to 7,075,471 shares of our common stock by selling stockholder - marketscreener.com
Aptevo Therapeutics Prospectus Relates To Offer And Sale Of Up To 7,075,471 Shares Of Our Common Stock By Selling Stockholder - TradingView
Aug Rallies: Is Aptevo Therapeutics Inc impacted by rising ratesJuly 2025 EndofMonth & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Growth Report: Can Compass Minerals International Inc. deliver consistent EPS growthInsider Selling & Community Verified Swing Trade Signals - baoquankhu1.vn
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Take Profit: Is Weave Communications Inc a defensive stock2025 Analyst Calls & Accurate Intraday Trading Signals - baoquankhu1.vn
VIX Spike: What are Aptevo Therapeutics Incs recent SEC filings showingTrade Exit Report & Fast Moving Market Watchlists - baoquankhu1.vn
Chipmakers Recap: Is NTNX stock overvalued or fairly priced2025 Buyback Activity & Reliable Price Action Trade Plans - baoquankhu1.vn
Aptevo Therapeutics (NASDAQ: APVO) seeks OK for $60M SEPA share sales - Stock Titan
Income Plays: Does Eastman Kodak Company align with a passive investing strategy - baoquankhu1.vn
Market Overview: How sensitive is HUHUTECH International Group Inc to inflationJuly 2025 Movers & Verified Momentum Stock Watchlist - baoquankhu1.vn
Aptevo Therapeutics (APVO) Price Target Increased by 1,700.00% to 7,711.20 - Nasdaq
Aptevo Therapeutics shares jump after $60 million equity facility secured - MSN
HOKA Size Guide: What valuation multiples suggest for Aptevo Therapeutics Inc. stockNew Releases Roundup & road comfort picks for daily use - Улправда
Aptevo Therapeutics Secures $60 Million Equity Financing Facility - The Globe and Mail
Aptevo Therapeutics Inc. (APVO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aptevo Therapeutics Inc Stock (APVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):